stoxline Quote Chart Rank Option Currency Glossary
Inventiva S.A. (IVA)
4.32  0.17 (4.1%)    12-01 15:45
Open: 4.175
High: 4.39
Volume: 3,898
Pre. Close: 4.15
Low: 4.175
Market Cap: 230(M)
Technical analysis
2023-12-01 4:20:49 PM
Short term     
Mid term     
Targets 6-month :  5.12 1-year :  5.98
Resists First :  4.38 Second :  5.12
Pivot price 4.03
Supports First :  3.88 Second :  3.56
MAs MA(5) :  4.26 MA(20) :  3.99
MA(100) :  3.89 MA(250) :  4.13
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  83.9 D(3) :  85.2
RSI RSI(14): 61.9
52-week High :  6.82 Low :  2.22
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IVA ] has closed below upper band by 16.3%. Bollinger Bands are 26% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.39 - 4.42 4.42 - 4.44
Low: 4.11 - 4.14 4.14 - 4.17
Close: 4.25 - 4.3 4.3 - 4.34
Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Headline News

Tue, 21 Nov 2023
Inventiva publie ses informations financières du 3ème trimestre ... - LaBourseEtLaVie

Sat, 21 Oct 2023
Shareholders in Inventiva (EPA:IVA) have lost 71%, as stock drops 12% this past week - Simply Wall St

Mon, 09 Oct 2023
ROTH MKM to Host Healthcare Opportunities Conference on ... - GlobeNewswire

Thu, 21 Sep 2023
Inventiva : La biotech Inventiva signe une licence pour sa molécule ... - BFM Bourse

Thu, 21 Sep 2023
Inventiva licenses NASH candidate for Japan, South Korea ... - BioWorld Online

Thu, 15 Jun 2023
AbbVie stock Coherus in legal battle over Humira biosimilar - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 52 (M)
Shares Float 14 (M)
Held by Insiders 0 (%)
Held by Institutions 12.1 (%)
Shares Short 91 (K)
Shares Short P.Month 76 (K)
Stock Financials
EPS -2.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.19
Profit Margin 0 %
Operating Margin -830.6 %
Return on Assets (ttm) -54.9 %
Return on Equity (ttm) -258.1 %
Qtrly Rev. Growth 95.1 %
Gross Profit (p.s.) 0.36
Sales Per Share 0.42
EBITDA (p.s.) -1.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -64 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -2.08
PEG Ratio 0
Price to Book value -23.89
Price to Sales 10.07
Price to Cash Flow -3.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android